Aequim Alternative Investments LP Supernus Pharmaceuticals, Inc. Transaction History

Aequim Alternative Investments LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 12, 2021	SELL	$24.15 - $31.45 $1.12 Million - $1.46 Million	-46,400 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $22.2 Million - $32.4 Million	-1,253,600 Reduced 96.43%	46,400 $1.17 Million
Q4 2020 Feb 10, 2021	BUY	$17.7 - $25.81 $22.2 Million - $32.4 Million	1,253,600 Added 2701.72%	1,300,000 $1.3 Million
Q1 2020 May 15, 2020	SELL	$14.45 - $24.69 $1.01 Million - $1.72 Million	-69,800 Reduced 60.07%	46,400 $835,000
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $695,072 - $901,783	23,200 Added 24.95%	116,200 $3.85 Million
Q1 2019 May 15, 2019	BUY	$32.77 - $41.99 $1.14 Million - $1.46 Million	34,800 Added 59.79%	93,000 $3.26 Million
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $1.79 Million - $2.88 Million	58,200 New	58,200 $1.93 Million

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Aequim Alternative Investments LP, based on Form 13F filings with the SEC.

Stay updated on Aequim Alternative Investments LP with notifications on news.